BioLife Solutions, Inc. (BLFS)

Over the past six months, BioLife Solutions' stock has been impacted by several events. On February 26, 2026, the company reported its Fourth Quarter and Full Year 2025 Financial Results, announcing revenue increases and providing 2026 revenue guidance. On February 17, 2026, the company announced the date for reporting its Q4 and full-year 2025 financial results. On February 12, 2026, BioLife Solutions signed a multi-year supply agreement with Qkine Limited. On March 2, 2026, the stock experienced a significant drop despite strong results. The company reported its Q3 2025 earnings on November 6, 2025, held its Annual General Meeting on August 20, 2025, and reported its Q2 2025 earnings on August 7, 2025.

The provided search results do not explicitly state a direct demand seasonality for BioLife Solutions' products and services. The company's growth is tied to the rapidly expanding cell and gene therapy market, with demand increasing as CGT development and biobanking become denser. This suggests a more consistent, growth-driven demand rather than strong seasonal fluctuations.

BioLife Solutions, Inc. is a life sciences company focused on bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. It provides cell processing tools and services, biopreservation media, and related solutions. Key products include CryoStor and HypoThermosol biopreservation media, CellSeal vials, hPL products, ThawSTAR product line, and CryoCase. The company generates most of its revenue from its Cell Processing segment and operates the Aby J. Mathew Center for Biopreservation Excellence.

BioLife Solutions' market presence is concentrated in North America, Western Europe, and select Asia-Pacific hubs. Its primary markets include the United States, Europe (Germany, UK, France, Spain, Benelux), and APAC (Japan, South Korea, Australia), with a growing presence in China. Key clusters include Boston/Cambridge, San Francisco Bay Area, Research Triangle, and Houston in the US; Cambridge/Oxford-London, Munich, and Basel in Europe; and Tokyo-Yokohama, Seoul, and Melbourne-Sydney in APAC. The company's headquarters are located in Bothell, Washington, United States.

BioLife Solutions has a strong reputation as a leader in the cell and gene therapy sector, particularly for its biopreservation media. Its CryoStor and HypoThermosol products are considered "gold-standard tools" and are embedded in multiple approved cell and gene therapies. The company's products are specified in more than 70% of U.S. cell-based therapy clinical trials and used in roughly 90% of commercially relevant FDA-approved cell-based therapies. However, its reputation has been affected by its inclusion on the "Cruelty Free Investing" list due to past animal testing practices.

Institutional investors are the dominant force in BioLife Solutions' ownership, holding a substantial majority of the company's shares. As of April 10, 2026, 189 institutional owners and shareholders held a total of 42,796,175 shares. Major institutional shareholders include Casdin Capital, LLC, BlackRock, Inc., and Invesco Ltd. Insider ownership stood at 1.85% as of July 2025.